Five physicians have joined the recently formed Breast Cancer Clinical Advisory Board for Anixa BioSciences, a biotechnology company working towards the treatment and prevention of cancer and infectious diseases.
The advisory board is composed of seven experts in the field, including five physicians and the company's chief development officer, according to a Feb. 21 release announcing the formation of the board.
Arnold Baskies, MD, is the chair of the American Cancer Society's Global Cancer Control Advisory Council. He specializes in general surgery and surgical oncology and is affiliated with Virtua Health.
G. Thomas Budd, MD, is the principal investigator for a phase 1 trial of Anixa's breast cancer vaccine through a partnership between Anixa and the Cleveland Clinic. A specialist in breast cancer, he also teaches as a professor of hematology and oncology at the Cleveland Clinic.
Brian Czerniecki, MD, PhD, is a physician scientist known for his work to develop vaccines for the prevention of breast cancer and other solid tumors, the release said. He is also chair of the Moffitt Cancer Center Department of Breast Oncology in Tampa, Fla.
Brian Leyland-Jones, MD, PhD, currently serves as chief medical officer for the AIM-HI Accelerator Fund, OTraces, and the N OF 1 Mission. He is also on the scientific advisory board for the National Foundation for Cancer Research.
Hope Rugo, MD, is the director of breast oncology and clinical trials education at the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco. In addition, she is a member of the Translational Breast Cancer Research Consortium.